CORT News Today: Stay Updated with the Latest Corcept Therapeutics Incorporated News in Real Time
Find CORT news now at Meyka AI. Stay informed with the latest{" "} Corcept Therapeutics Incorporated stocks updates, including price news, market analysis, and expert insights.
Abivax Shares Plunge 32% Despite Positive Colitis Trial Results Amid Safety Concerns
French biotech company Abivax delivered some of the strongest ulcerative colitis trial results seen in recent years. Yet, Abivax Shares (ABVX) plunged more than 32% on June 2, 2026, as investors focused on safety concerns rather than efficacy data. The selloff came after the company released positive Phase 3 maintenance trial results for its lead…
Trump’s Doctor Recommends Weight Loss After Physical, June 01
Trump’s doctor reports excellent health after May physical, recommending weight loss, exercise, and dietary guidance.
Paytm Shares Rise After Arm Announces €9 Million Investment in European Unit
Paytm shares moved higher after the company announced a fresh €9 million investment in its European subsidiary, Paytm Europe Payments S.A., on May 25, 2026. The Luxembourg-based unit is expected to support Paytm’s broader international expansion plans. Investors reacted positively as the move signals the fintech giant’s growing focus on global digital payments markets. With…
IMMX Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on IMMX, raises price target to $20 from $15 on May 22, 2026.
HLNE Earnings Beat: Hamilton Lane Q2 2026 EPS Tops Estimates
Hamilton Lane (HLNE) beat EPS estimates by 4.2% on May 21, 2026, but missed revenue expectations. Stock up 1.95% post-earnings.
XOMA Downgraded to Hold from Buy at Benchmark May 22
Benchmark downgraded XOMA to Hold from Buy on May 22, 2026. Stock trades at $41.65 with mixed analyst sentiment.
AHVBS Stock Surges 16.3 Billion Percent as RSE Archive Collectibles Platform Gains Traction
AHVBS stock jumps to $5.75 on collectibles trading platform momentum. RSE Archive trades on PNK exchange with strong volume surge.
ROIV Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Roivant Sciences (ROIV) at Overweight rating, citing mosliciguat Phase 2 catalysts and 2026 pipeline strength.
UTHR Maintained at Buy by Cowen & Co., May 2026
Cowen & Co. maintains Buy rating on United Therapeutics (UTHR) as a top biotech idea with strong fundamentals.